Sigma-Aldrich Acquires Research Organics to Strengthen Portfolio of PharmaGrade Raw Materials


Sigma-Aldrich Acquires Research Organics to Strengthen Portfolio of PharmaGrade Raw Materials

ST. LOUIS, April 2, 2012--Sigma-Aldrich Corporation (Nasdaq: SIAL) announced today it has acquired all outstanding shares of Cleveland, Ohio-based, Research Organics, Inc., to expand the Company's buffer production capacity and to increase its portfolio of PharmaGrade raw materials for the biopharmaceutical and diagnostic markets. Research Organics is a leading supplier of high purity biochemicals for use in molecular biology, diagnostics, cell culture, pharmaceuticals, biopharmaceuticals, life sciences and biotechnology and will transition into SAFC, the custom manufacturing and services business unit of Sigma-Aldrich.

"Research Organics is an important addition to our pharmaceutical grade portfolio of raw materials for the biopharmaceutical industry," said Gilles Cottier, Executive Vice President, Sigma-Aldrich, and President, SAFC. "This acquisition is an outstanding complement to our existing raw materials portfolio and will help us provide more innovative solutions for some of our customers' toughest supply challenges.  It will also enable us to provide SAFC's customers with true dual sourcing of buffers from two of the world's leading manufacturing sites."

Founded in the 1950's, Research Organics was a pioneer in manufacturing zwitterionic biological buffers and developing the HEPES buffer as an industry-standard.

"Joining Sigma-Aldrich is positive for Research Organics, our employees, customers and the city of Cleveland," said Rob Sternfeld, President of Research Organics. "The acquisition provides the resources to expand the growth of our business, to enhance our product line and to upgrade our facilities to meet ever changing industry requirements. We will continue to provide our customers with the superior quality and service they deserve and have come to expect."

Terms of the purchase were not disclosed. The Company expects this acquisition to be neutral to earnings per share in 2012.

Cautionary statement:  The foregoing release contains forward-looking statements that can be identified by terminology such as "will help," "will enable," "expand," "update," "expects" and variations of such words and similar expressions, or by expressed or implied discussions regarding potential future revenues, earnings and free cash flow from the acquisition of Research Organics. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the acquisition of Research Organics will achieve any particular levels of revenue in the future. In particular, management's expectations regarding the acquisition of Research Organics could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; Sigma-Aldrich's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's annual and quarterly reports on Form 10-K and Form 10-Q on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. It's recognized as a top 10 global fine chemical supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can often resolve development and manufacturing challenges and accelerate the production of custom materials. Its rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, biopharmaceutical lot release and safety testing, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology.  For more information about Sigma-Aldrich, please visit its website at

Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co. LLC registered in the US and other countries.

SOURCE Sigma-Aldrich Corporation

News Provided by Acquire Media